GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Raphas Co Ltd (XKRX:214260) » Definitions » EV-to-EBIT

Raphas Co (XKRX:214260) EV-to-EBIT : -32.93 (As of Apr. 30, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Raphas Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Raphas Co's Enterprise Value is ₩126,758 Mil. Raphas Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-3,849 Mil. Therefore, Raphas Co's EV-to-EBIT for today is -32.93.

The historical rank and industry rank for Raphas Co's EV-to-EBIT or its related term are showing as below:

XKRX:214260' s EV-to-EBIT Range Over the Past 10 Years
Min: -3260   Med: -39.87   Max: 84.14
Current: -32.93

During the past 10 years, the highest EV-to-EBIT of Raphas Co was 84.14. The lowest was -3260.00. And the median was -39.87.

XKRX:214260's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.18 vs XKRX:214260: -32.93

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Raphas Co's Enterprise Value for the quarter that ended in Dec. 2023 was ₩175,053 Mil. Raphas Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-3,849 Mil. Raphas Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.20%.


Raphas Co EV-to-EBIT Historical Data

The historical data trend for Raphas Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raphas Co EV-to-EBIT Chart

Raphas Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,372.46 -45.93 46.95 -20.57 -45.48

Raphas Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.57 -41.83 -42.08 -45.07 -45.48

Competitive Comparison of Raphas Co's EV-to-EBIT

For the Biotechnology subindustry, Raphas Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raphas Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Raphas Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Raphas Co's EV-to-EBIT falls into.



Raphas Co EV-to-EBIT Calculation

Raphas Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=126757.998/-3849.365
=-32.93

Raphas Co's current Enterprise Value is ₩126,758 Mil.
Raphas Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,849 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Raphas Co  (XKRX:214260) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Raphas Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-3849.365/175052.6632
=-2.20 %

Raphas Co's Enterprise Value for the quarter that ended in Dec. 2023 was ₩175,053 Mil.
Raphas Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,849 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Raphas Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Raphas Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Raphas Co (XKRX:214260) Business Description

Traded in Other Exchanges
N/A
Address
62, Magokjungang 8-ro 1-gil, Gangseo-gu, Seoul, KOR, 07793
Raphas Co Ltd is engaged in the development of a drug delivery system. The company's products include Acropass, Cosmetics ODM, and Medical Contract Manufacturing Services. Its products are mostly used in biomedical products and all-natural cosmetic materials.

Raphas Co (XKRX:214260) Headlines

No Headlines